Abstract
There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 133-140 |
| Number of pages | 8 |
| Journal | Magnesium research : official organ of the International Society for the Development of Research on Magnesium |
| Volume | 11 |
| Issue number | 2 |
| State | Published - Jun 1998 |
Fingerprint
Keywords
- Acute myocardial infarction
- Animal model
- Humans
- Magnesium
- Mechanisms
- Myocardial ischemia-reperfusion
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion : From animal studies to clinical trials. / Serebruany, Victor L.; Atar, Dan; Dalesandro, Margaret R.; O'Connor, Christopher M.; Gurbel, Paul A.
In: Magnesium research : official organ of the International Society for the Development of Research on Magnesium, Vol. 11, No. 2, 06.1998, p. 133-140.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion
T2 - From animal studies to clinical trials
AU - Serebruany, Victor L.
AU - Atar, Dan
AU - Dalesandro, Margaret R.
AU - O'Connor, Christopher M.
AU - Gurbel, Paul A.
PY - 1998/6
Y1 - 1998/6
N2 - There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.
AB - There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.
KW - Acute myocardial infarction
KW - Animal model
KW - Humans
KW - Magnesium
KW - Mechanisms
KW - Myocardial ischemia-reperfusion
UR - http://www.scopus.com/inward/record.url?scp=0032088418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032088418&partnerID=8YFLogxK
M3 - Article
C2 - 9675757
AN - SCOPUS:0032088418
VL - 11
SP - 133
EP - 140
JO - Magnesium Research
JF - Magnesium Research
SN - 0953-1424
IS - 2
ER -